This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
DURECT Corporation, a biopharmaceutical company, researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms.View DRRX
Durect Corp - DRRX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Durect Corp as a
Sell with a ratings score of D-.
Report Snippet: We rate DURECT CORP (DRRX) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself, feeble growth in its earnings per share and generally high debt management risk.